Pricing
  1. US-listed companies
  2. CymaBay Therapeutics, Inc.
  3. Financials
  4. EBITDA

CymaBay Therapeutics, Inc. (CBAY)

Market cap
$3.7B
P/E ratio
SummaryFinancials
Period EndEBITDA (Million USD)YoY (%)
Dec 31, 2023-101+9.30%
Dec 31, 2022-92+6.34%
Dec 31, 2021-87+67.20%
Dec 31, 2020-52-51.69%
Dec 31, 2019-108+48.59%
Dec 31, 2018-72+240.07%
Dec 31, 2017-21-16.70%
Dec 31, 2016-26-1.23%
Dec 31, 2015-26+7.86%
Dec 31, 2014-24+156.82%
Dec 31, 2013-9

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat